{"id":9039,"date":"2018-10-31T00:00:37","date_gmt":"2018-10-31T00:00:37","guid":{"rendered":"https:\/\/www.olartemoure.com\/?p=9039"},"modified":"2018-10-29T21:57:26","modified_gmt":"2018-10-29T21:57:26","slug":"united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira","status":"publish","type":"post","link":"https:\/\/olartemoure.com\/en\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\/","title":{"rendered":"United States: Fresenius Kabi achieves global agreement with AbbVie with respect to Fresenius adalimumab, a biosimilar candidate of AbbVie Humira"},"content":{"rendered":"

The German company Fresenius Kabi has sealed a worldwide settlement with AbbVie Inc<\/a>, concerting all pending patent litigations between the two companies. \u00a0Under the terms of the agreement, Fresenius Kabi\u2019s biosimilar candidate of Humira (adalimumab), could be commercialized in the United States from September 30, 2023.<\/p>\n

On 17 October 2018, licenses under the agreement came into effect in certain countries in Europe in which AbbVie owns Intellectual Property. \u00a0The application for marketing authorization for Humira was submitted by Fresenius Kabi to the European Medicines Agency (EMA) at the end of last year.<\/p>\n

Original source in English:
\nhttps:\/\/www.fresenius.com\/7195<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The German company Fresenius Kabi has sealed a worldwide settlement with AbbVie Inc, concerting all pending patent litigations between the two companies. \u00a0Under the terms of the agreement, Fresenius Kabi\u2019s biosimilar candidate of Humira (adalimumab), could be commercialized in the United States from September 30, 2023. On 17 October 2018, licenses under the agreement came […]<\/p>\n","protected":false},"author":2,"featured_media":9041,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[51,59],"tags":[],"class_list":["post-9039","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-patents","category-newsletter-en"],"yoast_head":"\nUnited States: Fresenius Kabi achieves global agreement with AbbVie with respect to Fresenius adalimumab, a biosimilar candidate of AbbVie Humira - OlarteMoure | Intellectual Property<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/olartemoure.com\/en\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"United States: Fresenius Kabi achieves global agreement with AbbVie with respect to Fresenius adalimumab, a biosimilar candidate of AbbVie Humira\" \/>\n<meta property=\"og:description\" content=\"The German company Fresenius Kabi has sealed a worldwide settlement with AbbVie Inc, concerting all pending patent litigations between the two companies. \u00a0Under the terms of the agreement, Fresenius Kabi\u2019s biosimilar candidate of Humira (adalimumab), could be commercialized in the United States from September 30, 2023. On 17 October 2018, licenses under the agreement came […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/olartemoure.com\/en\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\/\" \/>\n<meta property=\"og:site_name\" content=\"OlarteMoure | Intellectual Property\" \/>\n<meta property=\"article:published_time\" content=\"2018-10-31T00:00:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/olartemoure.com\/wp-content\/uploads\/2018\/10\/3.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"810\" \/>\n\t<meta property=\"og:image:height\" content=\"540\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Diego Bernal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Diego Bernal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\\\/\"},\"author\":{\"name\":\"Diego Bernal\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/b66ca4b152a396f32fd6e5c48395ce14\"},\"headline\":\"United States: Fresenius Kabi achieves global agreement with AbbVie with respect to Fresenius adalimumab, a biosimilar candidate of AbbVie Humira\",\"datePublished\":\"2018-10-31T00:00:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\\\/\"},\"wordCount\":117,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2018\\\/10\\\/3.jpg\",\"articleSection\":[\"Patents\",\"Newsletter\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\\\/\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\\\/\",\"name\":\"United States: Fresenius Kabi achieves global agreement with AbbVie with respect to Fresenius adalimumab, a biosimilar candidate of AbbVie Humira - OlarteMoure | Intellectual Property\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2018\\\/10\\\/3.jpg\",\"datePublished\":\"2018-10-31T00:00:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/b66ca4b152a396f32fd6e5c48395ce14\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/olartemoure.com\\\/en\\\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\\\/#primaryimage\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2018\\\/10\\\/3.jpg\",\"contentUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2018\\\/10\\\/3.jpg\",\"width\":810,\"height\":540},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"United States: Fresenius Kabi achieves global agreement with AbbVie with respect to Fresenius adalimumab, a biosimilar candidate of AbbVie Humira\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#website\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/\",\"name\":\"OlarteMoure | Intellectual Property\",\"description\":\"Firma especializada en Propiedad Intelectual\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/olartemoure.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/b66ca4b152a396f32fd6e5c48395ce14\",\"name\":\"Diego Bernal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/98e19bbd1dde17a81a7a8ac596fcdab15de47e6ad6983172a99e27f2b531058b?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/98e19bbd1dde17a81a7a8ac596fcdab15de47e6ad6983172a99e27f2b531058b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/98e19bbd1dde17a81a7a8ac596fcdab15de47e6ad6983172a99e27f2b531058b?s=96&d=mm&r=g\",\"caption\":\"Diego Bernal\"},\"url\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/author\\\/dsb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"United States: Fresenius Kabi achieves global agreement with AbbVie with respect to Fresenius adalimumab, a biosimilar candidate of AbbVie Humira - OlarteMoure | Intellectual Property","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/olartemoure.com\/en\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\/","og_locale":"en_US","og_type":"article","og_title":"United States: Fresenius Kabi achieves global agreement with AbbVie with respect to Fresenius adalimumab, a biosimilar candidate of AbbVie Humira","og_description":"The German company Fresenius Kabi has sealed a worldwide settlement with AbbVie Inc, concerting all pending patent litigations between the two companies. \u00a0Under the terms of the agreement, Fresenius Kabi\u2019s biosimilar candidate of Humira (adalimumab), could be commercialized in the United States from September 30, 2023. On 17 October 2018, licenses under the agreement came […]","og_url":"https:\/\/olartemoure.com\/en\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\/","og_site_name":"OlarteMoure | Intellectual Property","article_published_time":"2018-10-31T00:00:37+00:00","og_image":[{"width":810,"height":540,"url":"https:\/\/olartemoure.com\/wp-content\/uploads\/2018\/10\/3.jpg","type":"image\/jpeg"}],"author":"Diego Bernal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Diego Bernal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/olartemoure.com\/en\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\/#article","isPartOf":{"@id":"https:\/\/olartemoure.com\/en\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\/"},"author":{"name":"Diego Bernal","@id":"https:\/\/olartemoure.com\/#\/schema\/person\/b66ca4b152a396f32fd6e5c48395ce14"},"headline":"United States: Fresenius Kabi achieves global agreement with AbbVie with respect to Fresenius adalimumab, a biosimilar candidate of AbbVie Humira","datePublished":"2018-10-31T00:00:37+00:00","mainEntityOfPage":{"@id":"https:\/\/olartemoure.com\/en\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\/"},"wordCount":117,"commentCount":0,"image":{"@id":"https:\/\/olartemoure.com\/en\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\/#primaryimage"},"thumbnailUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2018\/10\/3.jpg","articleSection":["Patents","Newsletter"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/olartemoure.com\/en\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\/","url":"https:\/\/olartemoure.com\/en\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\/","name":"United States: Fresenius Kabi achieves global agreement with AbbVie with respect to Fresenius adalimumab, a biosimilar candidate of AbbVie Humira - OlarteMoure | Intellectual Property","isPartOf":{"@id":"https:\/\/olartemoure.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/olartemoure.com\/en\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\/#primaryimage"},"image":{"@id":"https:\/\/olartemoure.com\/en\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\/#primaryimage"},"thumbnailUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2018\/10\/3.jpg","datePublished":"2018-10-31T00:00:37+00:00","author":{"@id":"https:\/\/olartemoure.com\/#\/schema\/person\/b66ca4b152a396f32fd6e5c48395ce14"},"breadcrumb":{"@id":"https:\/\/olartemoure.com\/en\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/olartemoure.com\/en\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/olartemoure.com\/en\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\/#primaryimage","url":"https:\/\/olartemoure.com\/wp-content\/uploads\/2018\/10\/3.jpg","contentUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2018\/10\/3.jpg","width":810,"height":540},{"@type":"BreadcrumbList","@id":"https:\/\/olartemoure.com\/en\/united-states-fresenius-kabi-achieves-global-agreement-with-abbvie-with-respect-to-fresenius-adalimumab-a-biosimilar-candidate-of-abbvie-humira\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/olartemoure.com\/en\/"},{"@type":"ListItem","position":2,"name":"United States: Fresenius Kabi achieves global agreement with AbbVie with respect to Fresenius adalimumab, a biosimilar candidate of AbbVie Humira"}]},{"@type":"WebSite","@id":"https:\/\/olartemoure.com\/#website","url":"https:\/\/olartemoure.com\/","name":"OlarteMoure | Intellectual Property","description":"Firma especializada en Propiedad Intelectual","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/olartemoure.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/olartemoure.com\/#\/schema\/person\/b66ca4b152a396f32fd6e5c48395ce14","name":"Diego Bernal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/98e19bbd1dde17a81a7a8ac596fcdab15de47e6ad6983172a99e27f2b531058b?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/98e19bbd1dde17a81a7a8ac596fcdab15de47e6ad6983172a99e27f2b531058b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/98e19bbd1dde17a81a7a8ac596fcdab15de47e6ad6983172a99e27f2b531058b?s=96&d=mm&r=g","caption":"Diego Bernal"},"url":"https:\/\/olartemoure.com\/en\/author\/dsb\/"}]}},"_links":{"self":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts\/9039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/comments?post=9039"}],"version-history":[{"count":0,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts\/9039\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/media\/9041"}],"wp:attachment":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/media?parent=9039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/categories?post=9039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/tags?post=9039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}